Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.380
0.00 (0.00%)
At close: Nov 18, 2026, 4:00 PM EST
1.390
+0.010 (0.72%)
After-hours: Nov 18, 2026, 4:20 PM EST
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $277.16 million as of November 18, 2026. It is the 18,251st most valuable company in the world and the 3,217th biggest in the United States. Its market cap has increased by 101.06% in one year.
Market Cap
277.16M
Enterprise Value
83.84M
1-Year Change
101.06%
Global Rank
Country Rank
#3,217 United States
Category
ChartMarket Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $277.16M, an increase of 175.90%. That is a compound annual growth rate of 18.75%.
| Date | Market Cap | % Change |
|---|---|---|
| Nov 18, 2026 | 277.16M | -1.16% |
| Dec 31, 2025 | 280.40M | -3.25% |
| Dec 31, 2024 | 289.83M | 3,596.14% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 23, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Evommune | 315.50M |
| Larimar Therapeutics | 315.24M |
| AgomAb Therapeutics NV | 313.22M |
| Autolus Therapeutics | 311.41M |
| Scribe Therapeutics | 309.82M |
| Galectin Therapeutics | 307.59M |
| Agenus | 304.51M |
| PepGen | 301.97M |